Mereo acquired a portfolio of three product candidates from Novartis in July 2015 including setrusumab (BPS-804), acumapimod (BCT-197), and leflutrozole (BGS-649).
The company in-licensed alvelestat (MPH-966) from AstraZeneca in October 2017.